Anto Biopharma

Anto Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for oncology. The company utilizes a proprietary structure-based drug design platform to target well-validated but challenging oncogenic drivers, such as KRAS and EGFR mutations. Its lead program, AT-001, is a selective KRAS G12C inhibitor currently in Phase 1/2 clinical trials for solid tumors. Anto Biopharma aims to address significant unmet medical needs and overcome drug resistance mechanisms in cancers like non-small cell lung cancer and colorectal cancer. With operations in both Suzhou, China, and California, USA, the company maintains a global perspective on drug development and clinical strategy. Anto is backed by prominent life science investors and led by an experienced management team with a track record in global pharmaceutical R&D.